Answers are grounded in this paper and cite their sources.
BackgroundBelatacept is a relevant alternative to calcineurin-inhibitors after kidney transplantation. Circulating Torque Teno Virus (TTV) DNA load is correlated to infectious and rejection risks post-kidney transplantation in calcineurin-inhibitors treated patients. The aim of this study was to assess the TTV DNA load profile in kidney transplant recipients converted from calcineurin-inhibitors to Belatacept and explore its use as a predictive biomarker.MethodsSixty-eight single-center kidney transplanted recipients converted from calcineurin-inhibitors to Belatacept between June-2015 and December-2020 were included. Whole blood TTV DNA load was measured before, at 3-, 6- and 12-months post-belatacept conversion. Our primary endpoint was to assess the TTV DNA load profile and correlate the results with rejection and opportunistic infection.ResultsTTV DNA load remained stable after Belatacept conversion, i.e., 3.8 [3.1-4.9], 4.4 [3.2-5.4], 4.0 [3.0-5.7] and 4.2 [3.0- 5.2] log10 copies/ml at baseline, 3-, 6- and 12-months respectively. No correlation was found between TTV DNA load and post-kidney transplantation complications. Chronic allograft dysfunction at one-year post-conversion was associated with a lower TTV DNA load after 6- and 12-months (P = 0.014 and P = 0.021). A higher TTV DNA load was found in older patients, and in those with higher body mass index (P = 0.023 and P = 0.005).ConclusionCalcineurin-inhibitors to belatacept conversion did not affect TTV DNA load. Opportunistic infections or acute rejection occurrences were not associated with TTV DNA load. However, low TTV DNA load after 6 months post-conversion may be a promising tool to predict graft dysfunction risk at 1-year post-conversion.
No takes yet. Share an insight, caveat, or question.
Cabezas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: